IRESSA® (gefitinib)

Iressa® (gefitinib) is een remmer van de epidermale groeifactor-receptor tyrosinekinase (EGFR-TK) voor de behandeling van gevorderde niet-kleincellige longkanker (NSCLC).


  1. IRESSA, samenvatting van de productkenmerken, meest recente versie.
  2. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
  3. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866-2874.
  4. Douillard JY, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer. 2014;110(1):55-62.
  5. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-2388.
  6. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121-128.
  7. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist. 2003;8(4):303-306.
  8. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) with NCCN Evidence Blocks™ for Non-Small Cell Lung Cancer V.4.2016. © National Comprehensive Cancer Network, Inc. 2016. All rights reserved.Accessed March 28, 2016. NCCN org NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
  9. Mok TSK, Saijo N, Thongprasert S, et al. Progression-free survival (PFS) according to blind independent central review (BICR): a post-hoc analysis from the phase III, multicenter, randomized IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced non-small-cell lung cancer (aNSCLC). Poster presented at the 16th Annual International Lung Cancer Congress; July 30-August 1, 2015; Huntington Beach, CA. Poster. 2016.

NS ID: XL-1026-RD04/2018-WEB Local code 410